2. Signaling Pathways
  3. Anti-infection
  4. SARS-CoV

SARS-CoV

SARS coronavirus

SARS-CoV

Related Products

PDF 0.94 MB

SARS-CoV is the coronavirus (CoV) that causes severe acute respiratory syndrome (SARS). CoVs are enveloped viruses with a positive-sense, single-stranded RNA and can cause health-threatening outbreaks by targeting human respiratory system, including not only SARS, but also Middle East respiratory syndrome (MERS) and SARS-CoV-2 (the cause of COVID-19).

CoVs have four main structural proteins: spike(S), membrane (M), envelope (E), and nucleocapsid (N) proteins. An S protein mediates the CoV entry into host cells by attaching to a cellular receptor (ACE2 for SARS-CoV and SARS-CoV-2, DPP4 for MERS-CoV), followed by fusion between virus and host cell membranes. Genome replication and subgenomic RNA transcription after entry carry on with the participation of many nonstructural proteins such as Mpro (main protease or 3CLpro), PLpro (papain-like protease) and RdRp (RNA-dependent RNA polymerase). Then the structural proteins are translated, assembled into mature virions, and released via vesicles by exocytosis. It is worth mentioning that a protease called TMPRSS2 (transmembrane protease, serine 2) play important roles throughout the whole life of CoVs (such as attachment, assembling and release) by cleaving S protein. All the proteins and subcellular structures participated in the life cycle of CoVs are promising targets for treatment of disease caused by CoVs.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-155488
    SHEN26
    		99.10%
    SHEN26 (ATY014) is a potent and orally active RdRp inhibitor, with an IC50 for SARS-CoV-2 is 1.36 μM. SHEN26 is a 5’-cyclohexanecarboxylate derivative of GS-441524 (HY-103586). SHEN26 inhibits viral nucleic acid synthesis to achieve antiviral effects. SHEN26 can be used for the research of coronavirus disease 2019 (COVID-19).
    SHEN26
  • HY-W039454
    2,4-Dichlorobenzyl alcohol
    		99.84%
    2,4-Dichlorobenzyl alcohol is an orally active mild antiseptic, with a broad spectrum for bacterial and virus associated with mouth and throat infections. 2,4-Dichlorobenzyl alcohol exhibits prenatal developmental toxicity.2,4-Dichlorobenzyl alcohol can be used in the study of SARS-CoV.
    2,4-Dichlorobenzyl alcohol
  • HY-145592
    Ruzotolimod
    		99.92%
    Ruzotolimod (RO7020531) is an orally active TLR7 agonist. Ruzotolimod inhibits WHV viral replication and, in combination with RO-7049389 (HY-145579), inhibits AAV-HBV viral load. Ruzotolimod can be used to study infection with COVID-19 or SARS-CoV-2.
    Ruzotolimod
  • HY-B0260S4
    Methylprednisolone-d2
    		Inhibitor 99.11%
    Methylprednisolone-d2 is the deuterium labeled Methylprednisolone. Methylprednisolone is a synthetic corticosteroid with anti-inflammatory and immunomodulating properties. Methylprednisolone improve severe or critical COVID-19 by activating ACE2 and reducing IL-6 levels.
    Methylprednisolone-d<sub>2</sub>
  • HY-113225S3
    Guanosine triphosphate-15N5 dilithium
    Guanosine triphosphate-15N5 (GTP-15N5) dilithium is 15N labeled Guanosine triphosphate (HY-113225). Guanosine triphosphate is a native nucleotide. The derivatives of GTP may be used as specific inhibitors against COVID-19.
    Guanosine triphosphate-<sup>15</sup>N<sub>5</sub> dilithium
  • HY-172760
    CIM-834
    		Inhibitor
    CIM-834 is an orally active and selective inhibitor targeting the coronavirus membrane protein (M protein), which potently blocks viral assembly against SARS-CoV-2 and SARS-CoV. CIM-834 binds to the short form of the M protein (Mshort) in a non-covalent manner, stabilizing Mshort and preventing its conformational switch to the long form (Mlong) required for virion assembly, thereby inhibiting viral particle formation. CIM-834 is promising for research of COVID-19 and other coronavirus infections.
    CIM-834
  • HY-124304
    Pinokalant
    		Inhibitor 99.09%
    Pinokalant is a broad-spectrum and non-selectivecation channel inhibitor. Pinokalant significantly reduces cortical infarct volume. Pinokalant o improves the metabolic and electrophysiologic status of the ischemic penumbra. Pinokalant reduces lesion size on magnetic resonance images in the acute phase following middle cerebral artery occlusion in rats. Pinokalant has the potential for the research of stroke. Pinokalant also shows anti-SARS-CoV-2 activity.
    Pinokalant
  • HY-P4388
    Z-Arg-Leu-Arg-Gly-Gly-AMC
    		99.93%
    Z-Arg-Leu-Arg-Gly-Gly-AMC is a peptide substrate of SARS-CoV PLpro.
    Z-Arg-Leu-Arg-Gly-Gly-AMC
  • HY-139442
    RdRP-IN-2
    		Inhibitor 98.01%
    RdRP-IN-2 is a RNA dependent RNA polymerase (RdRp) inhibitor. RdRP-IN-2 significantly inhibits SARS-CoV-2 RdRp with an IC50 of 41.2 μM.RdRP-IN-2 also inhibits Feline coronavirus (FIPV) replication.
    RdRP-IN-2
  • HY-137984
    Cnicin
    		Inhibitor 99.88%
    Cnicin is an orally bioavailable sesquiterpene lactone. Cnicin has antibacterial and antiproliferative properties and induces apoptosis in primary myeloma cells. Cnicin also exhibits activity against SARS-CoV-2. Cnicin inhibits the viral replication of SARS CoV-2 with an IC50 of 1.18 μg/mL. Cnicin can promote functional nerve regeneration.
    Cnicin
  • HY-N10109A
    Gallinamide A TFA
    		Inhibitor 99.85%
    Gallinamide A TFA is a linearly depositing peptide and a potent inhibitor of cathepsin L (CatL) (IC50: 17.6 pM). Gallinamide A TFA inhibits SARS-CoV-2 infection by inhibiting CatL (EC50: 28 nM). Gallinamide A TFA also inhibits Plasmodium falciparum (IC50: 50 nM).
    Gallinamide A TFA
  • HY-149954
    SARS-CoV-2-IN-39
    		Inhibitor 99.79%
    SARS-CoV-2-IN-39 (compound 21) is a SARS-CoV-2 inhibitor with an EC50 of 1 μM. SARS-CoV-2-IN-39 against SARS-CoV-2 by inhibiting of SKP2 protein and stabilizing BECN1.
    SARS-CoV-2-IN-39
  • HY-P99467
    Beludavimab
    		Inhibitor
    Beludavimab (BMS 4182137; VIR 7832) is a monoclonal antibody targeting the spike glycoprotein of SARS-CoV-2. Beludavimab binds to recombinant spike protein receptor-binding domain (S-RBD) with an EC50 value of 14.9 ng/mL and a Kd of 0.21 nM.
    Beludavimab
  • HY-101046
    Quipazine dimaleate
    		Inhibitor 99.96%
    Quipazine dimaleate is a 5-HT agonist with a Ki value of 1.4 nM for displaces [3H]GR65630 from 5-HT3R in rat. Quipazine dimaleate shows antiviral activity against SARS-CoV-2 with an EC50 of 31.64 μM. Quipazine dimaleate behaves as a 5-HT3R antagonist in peripheral models. Quipazine dimaleate can be used for neurological disease research.
    Quipazine dimaleate
  • HY-169092
    PF-07957472
    		Inhibitor
    PF-07957472 (Compound 4) is an orally active SARS-CoV-2 papain-like protease (PLpro) inhibitor. PF-07957472 shows cytopathic effect in SARS-CoV-2 infected NHBE cells (EC50 = 13.9 nM). PF-07957472 shows antiviral effect in a mouse-adapted model of COVID-19 infection model.
    PF-07957472
  • HY-101984R
    N6,N6-Dimethyladenosine (Standard)
    		Inhibitor
    N6,N6-Dimethyladenosine (Standard) is the analytical standard of N6,N6-Dimethyladenosine (HY-101984). This product is intended for research and analytical applications. N6,N6-Dimethyladenosine, a modified ribonucleoside, is an endogenous A3 adenosine receptor ligand. N6,N6-Dimethyladenosine is an AKT inhibitor with antitumor effects. N6, N6-Dimethyladenosine targets SARS-CoV-2 entry protein ADAM17. N6, N6-Dimethyladenosine robustly inhibits AKT signaling in a variety of non-small cell lung cancer cell lines.
    N6,N6-Dimethyladenosine (Standard)
  • HY-155144
    CDD-1845
    		Inhibitor 99.60%
    CDD-1845 is a non-covalent and non-peptide potent SARS-CoV-2 Mpro inhibitor with a Ki of 3 nM. CDD-1845 also inhibits ΔP168, A173V, and ΔP168/A173V Mpro variants.
    CDD-1845
  • HY-126419
    Kobophenol A
    		Inhibitor 99.90%
    Kobophenol A, an oligomeric stilbene, blocks the interaction between the ACE2 receptor and S1-RBD with an IC50 of 1.81 μM and inhibits SARS-CoV-2 viral infection in cells with an EC50 of 71.6 μM. Kobophenol A inhibits the activity of partially purified rat brain protein kinase C (PKC) with an IC50 of 52 µM.
    Kobophenol A
  • HY-144800
    FWM-1
    		Inhibitor
    FWM-1 is a potent SARS-COV-2 NSP13 helicase enzyme inhibitor with binding free energy equals -328.6 kcal/mol. FWM-1 effectively disrupts the binding of ATP to the SARS-COV2 helicase enzyme.
    FWM-1
  • HY-N1910
    4'-O-Methylbavachalcone
    		Inhibitor 99.64%
    4'-O-Methylbavachalcone is a chalcone isolated from Psoralea corylifolia, inhibits severe acute respiratory syndrome coronavirus (SARS-CoV) papain-like protease (PLpro) activity, with an IC50 of 10.1 μM.
    4'-O-Methylbavachalcone
Cat. No. Product Name / Synonyms Species Source